HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo trial for advanced cancers ends early
Disease control TerminatedThis early-stage trial tested a new drug (TNO155) combined with either spartalizumab or ribociclib in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The main goal was to check safety and find the right dose. The study was terminated early,…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 01, 2026 15:26 UTC
-
New drug combo tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated May 01, 2026 15:25 UTC
-
Experimental cancer drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that had stopped responding to standard treatments. The trial was stopped early, so results are limited. About 192 participants were planned, and…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 01, 2026 15:24 UTC
-
Tiny drug particles tested to boost immune attack on head and neck tumors
Knowledge-focused TerminatedThis early study tested a new version of the chemotherapy drug paclitaxel, called FID-007, in one person with head and neck cancer. The drug is wrapped in a special polymer to help it reach deeper into tumors while sparing healthy cells. The goal was to see how it changes immune …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:03 UTC